So not long now for an update on Janssen collaboration. It does seem like forever, but CREDENCE was a very large study, 4000 plus cohort. Within the next 2 months as @katy & others have pointed out.
Some news on Invokana FYI, extra indications for kidney disease & cardiovascular disease granted in Canada. EU EMA decision is due anytime now (Fast track application accepted in August 2019 by EMA ~150 days timeframe) and important as we already have CE Mark for PromarkerD in EU.
Had a quick read through the quarterly, the below I think is a very important addition for PIQ in analytics. We are already engaged in clinical trial analysis for a bio similar for Xolair (Omalizumab). This space is HUGE & I think a very forward thinking addition to PIQ’s services:
”Proteomics International also took advantage of the downtime associated with its equipment upgrade to develop and launch a new specialist service for glycan analysis of biosimilars. This is an important addition to the Company's portfolio of services that are used to assess the quality of a biosimilar product, with the use of biosimilar drugs in the treatment of cancers continuing to expand.”
Also good to see PIQ are now continuing on with Endometriosis & Giardia tests in their pipeline. Maybe in earlier stages of development, but valuable all the same.
SP remains on a bit of a roller coaster ride, I’m not sure if that also may have something to do with concerns about what will happen in markets with the Corona virus affect & China? & not just our Quarterly.
Investment in analytics & equipment is vital to PIQ to continue their good work, & that doesn’t come cheap. If you want to tie in the whole Global Warming debate here too, I guess you could, with agricultural & marine analysis & drought. The world still needs to be fed.
Just a couple of thoughts. Have a great weekend all.
PIQ Price at posting:
27.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)